Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31. https://doi.org/10.1016/S0140-6736(02)08220-X.
Mohr DC, Hart SL, Fonareva I, Tasch ES. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006;12(2):204–8. https://doi.org/10.1191/135248506ms1265oa.
Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–17. https://doi.org/10.1177/1352458514564487.
Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020;11:851. https://doi.org/10.3389/fneur.2020.00851.
Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–17. https://doi.org/10.1038/nrneurol.2014.139.
Chou IJ, Kuo CF, Tanasescu R, Tench CR, Tiley CG, Constantinescu CS, Whitehouse WP. Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. Eur J Neurol. 2020;27(1):105–12. https://doi.org/10.1111/ene.14040.
Kalb R, Feinstein A, Rohrig A, Sankary L, Willis A. Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations. Curr Neurol Neurosci Rep. 2019;19(10):77. https://doi.org/10.1007/s11910-019-0992-1.
Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862–8. https://doi.org/10.1176/appi.ajp.159.11.1862.
Coplan JD, Aaronson CJ, Panthangi V, Kim Y. Treating comorbid anxiety and depression: psychosocial and pharmacological approaches. World J Psychiatry. 2015;5(4):366–78. https://doi.org/10.5498/wjp.v5.i4.366.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–66. https://doi.org/10.1016/S0140-6736(17)32802-7.
Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(7):581–601. https://doi.org/10.1016/S2215-0366(20)30137-1.
Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5:CD013674. https://doi.org/10.1002/14651858.CD013674.pub2.
Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73(10):613–27. https://doi.org/10.1111/pcn.12902.
Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord. 2017;18:177–80. https://doi.org/10.1016/j.msard.2017.10.004.
Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Patten SB, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Singer A, Marrie RA, Burden CTDT, D. Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26. https://doi.org/10.1016/j.msard.2015.10.004.
Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O’Connor C, Fitzpatrick C, Pasillas MP, Pena M, Adair A, Gonda DD, Levy ML, Ransohoff RM, Gage FH, Glass CK. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017. https://doi.org/10.1126/science.aal3222.
Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Bruck W. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol. 2013;125(4):595–608. https://doi.org/10.1007/s00401-013-1082-0.
Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112–23. https://doi.org/10.1016/j.molmed.2018.11.005.
Xia Z, Friedlander RM. Minocycline in multiple sclerosis—compelling results but too early to tell. N Engl J Med. 2017;376(22):2191–3. https://doi.org/10.1056/NEJMe1703230.
Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. Trends Neurosci. 2015;38(10):637–58. https://doi.org/10.1016/j.tins.2015.08.001.
Felger JC. Imaging the role of inflammation in mood and anxiety-related disorders. Curr Neuropharmacol. 2018;16(5):533–58. https://doi.org/10.2174/1570159X15666171123201142.
Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988–1000. https://doi.org/10.1038/sj.mp.4002006.
Jia X, Gao Z, Hu H. Microglia in depression: current perspectives. Sci China Life Sci. 2021;64(6):911–25. https://doi.org/10.1007/s11427-020-1815-6.
McKim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, Ramirez-Chan K, Wang Y, Roeth RM, Sucaldito AD, Sobol CG, Quan N, Sheridan JF, Godbout JP. Microglial recruitment of IL-1beta-producing monocytes to brain endothelium causes stress-induced anxiety. Mol Psychiatry. 2018;23(6):1421–31. https://doi.org/10.1038/mp.2017.64.
Yasumoto Y, Stoiljkovic M, Kim JD, Sestan-Pesa M, Gao XB, Diano S, Horvath TL. Ucp2-dependent microglia-neuronal coupling controls ventral hippocampal circuit function and anxiety-like behavior. Mol Psychiatry. 2021;26(7):2740–52. https://doi.org/10.1038/s41380-021-01105-1.
Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, Guo G, Yu H, Ma Y, Wang J, Chen S, Jing J, Yang J, Tang Y, Tang Z. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(1):21–32. https://doi.org/10.1136/jnnp-2019-320912.
Husain MI, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, Hodsoll J, Qurashi I, Deakin JF, Young AH. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol. 2017;31(9):1166–75. https://doi.org/10.1177/0269881117724352.
Sorensen PS, Sellebjerg F, Lycke J, Farkkila M, Creange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K, Investigators RS. Minocycline added to subcutaneous interferon beta-1a in multiple sclerosis: randomized RECYCLINE study. Eur J Neurol. 2016;23(5):861–70. https://doi.org/10.1111/ene.12953.
Chen W, Zhang HT, Qin SC. Neuroprotective effects of molecular hydrogen: a critical review. Neurosci Bull. 2021;37(3):389–404. https://doi.org/10.1007/s12264-020-00597-1.
Zhang Y, Su WJ, Chen Y, Wu TY, Gong H, Shen XL, Wang YX, Sun XJ, Jiang CL. Effects of hydrogen-rich water on depressive-like behavior in mice. Sci Rep. 2016;6:23742. https://doi.org/10.1038/srep23742.
Pilchova I, Klacanova K, Tatarkova Z, Kaplan P, Racay P. The involvement of Mg(2+) in regulation of cellular and mitochondrial functions. Oxid Med Cell Longev. 2017;2017:6797460. https://doi.org/10.1155/2017/6797460.
Nielsen FH. Magnesium deficiency and increased inflammation: current perspectives. J Inflamm Res. 2018;11:25–34. https://doi.org/10.2147/JIR.S136742.
Shahi A, Aslani S, Ataollahi M, Mahmoudi M. The role of magnesium in different inflammatory diseases. Inflammopharmacology. 2019;27(4):649–61. https://doi.org/10.1007/s10787-019-00603-7.
Zheltova AA, Kharitonova MV, Iezhitsa IN, Spasov AA. Magnesium deficiency and oxidative stress: an update. Biomedicine (Taipei). 2016;6(4):20. https://doi.org/10.7603/s40681-016-0020-6.
Du J, Zhu M, Bao H, Li B, Dong Y, Xiao C, Zhang GY, Henter I, Rudorfer M, Vitiello B. The role of nutrients in protecting mitochondrial function and neurotransmitter signaling: implications for the treatment of depression, PTSD, and suicidal behaviors. Crit Rev Food Sci Nutr. 2016;56(15):2560–78. https://doi.org/10.1080/10408398.2013.876960.
Eby GA 3rd, Eby KL. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses. 2010;74(4):649–60. https://doi.org/10.1016/j.mehy.2009.10.051.
Yu Z, Sun D, Feng J, Tan W, Fang X, Zhao M, Zhao X, Pu Y, Huang A, Xiang Z, Cao L, He C. MSX3 switches microglia polarization and protects from inflammation-induced demyelination. J Neurosci. 2015;35(16):6350–65. https://doi.org/10.1523/JNEUROSCI.2468-14.2015.
Chu X, Zhou Y, Hu Z, Lou J, Song W, Li J, Liang X, Chen C, Wang S, Yang B, Chen L, Zhang X, Song J, Dong Y, Chen S, He L, Xie Q, Chen X, Li W. 24-hour-restraint stress induces long-term depressive-like phenotypes in mice. Sci Rep. 2016;6:32935. https://doi.org/10.1038/srep32935.
Lu F, Yin D, Pu Y, Liu W, Li Z, Shao Q, He C, Cao L. Shikimic acid promotes oligodendrocyte precursor cell differentiation and accelerates remyelination in mice. Neurosci Bull. 2019;35(3):434–46. https://doi.org/10.1007/s12264-018-0322-7.
Wiebe S, Nagpal A, Truong VT, Park J, Skalecka A, He AJ, Gamache K, Khoutorsky A, Gantois I, Sonenberg N. Inhibitory interneurons mediate autism-associated behaviors via 4E-BP2. Proc Natl Acad Sci U S A. 2019;116(36):18060–7. https://doi.org/10.1073/pnas.1908126116.
留言 (0)